Sale

Diabetic Neuropathy Market

Global Diabetic Neuropathy Market Size, Share, Forecast: By Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy; By Treatment Methods: Antidepressants, Anti-seizure Medications, Anticonvulsants, Others; By Distribution Channels; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Diabetic Neuropathy Market Outlook

The diabetic neuropathy market size was valued at USD 4.90 billion in 2023, driven by the increasing prevalence of diabetic patients across the major regions. The market size is anticipated to grow at a CAGR of 6.99% during the forecast period of 2024-2032 to achieve a value of USD 8.50 billion by 2032.

 

Diabetic Neuropathy Market: Introduction

Diabetic neuropathy is a condition that causes nerve damage in people with diabetes. Nerves are damaged by high blood sugar in diabetics, resulting in diabetic neuropathy. Legs and feet are the most severely affected body parts in this condition. There are also symptoms associated with neuropathy, such as pain and numbness, depending on the nerves affected, such as peripheral nerves, autonomic nerves, proximal nerves, and focal nerves. Following are the different types of diabetic neuropathy:

 

Global Diabetic Neuropathy Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

  • Peripheral neuropathy affects the legs and feet.
  • Autonomic neuropathy affects the digestive system, primarily the stomach.
  • Proximal neuropathy affects buttocks and thighs.

 

Diabetes is a condition which needs to be treated at the earliest before it leads to severe consequences. It is not possible to cure neuropathic changes or provide pain relief with a single treatment. Various approaches are used to manage diabetic neuropathy, including intensive glucose control, treatment of risk factors, and treatment based on pathogenetic mechanisms.

 

The rapidly rising number of diabetic neuropathies and increased awareness in the next few years will compel major companies to launch new products. Thus, key players in the market are developing technologically advanced products to gain a competitive edge.

 

Global Diabetic Neuropathy Market Segmentations

The market can be segmented into categories like type, treatment methods, distribution channels, end user, and region.

 

Global Diabetic Neuropathy Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

 

Market Breakup by Treatment Methods

  • Antidepressants
  • Anti-seizure Medications
  • Anticonvulsants
  • Electric Nerve Stimulation
  • Topical Medications
  • Others

 

Market Breakup by Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

 

Market Breakup by End User

  • Hospitals
  • Research Institutes
  • Specialty Clinics

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific 
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America 
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa 
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Diabetic Neuropathy Market Scenario

The steep rise in diabetes cases will propel the growth of the market during the forecast period. The complications related to diabetes, cardiovascular diseases, obesity, and other complications related to glucose control contribute to neuropathy development. This includes the development of new products by manufacturers that are effective at treating neuropathy.

 

Global Diabetic Neuropathy Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Additionally, increased urbanization is causing unhealthy lifestyles like unhealthy food consumption, sedentary living, and others that adversely affect the market growth. Other factors driving the growth of the diabetic neuropathy market include ageing population, growing health care facilities, and increasing health care costs.

 

Diabetic neuropathy drugs are becoming increasingly expensive, and alternative treatments for the condition are also available readily available. These factors are hindering the growth of the global market.

 

Availability of alternative treatments, such as radiotherapy and physical therapy, that may improve patient outcomes, is also obstructing the growth of the market. Other factors that could hamper the market growth include regulations, product recalls, and FDA approval delays.

 

Regional Outlook for the Diabetic Neuropathy Market

North America is leading the global market owing to the increasing prevalence of diabetes. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.

 

It is also estimated that the Asia Pacific region is expected to grow at the fastest rate during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.

 

Diabetic Neuropathy Market Therapeutic Landscape

People with diabetes can be affected by diabetic neuropathy, a chronic debilitating condition. The objective assessment of diabetic neuropathy makes it difficult to diagnose and evaluate in clinical trials. Currently, there is no treatment available to prevent or reverse neuropathy or to relieve pain completely.

 

Diabetic neuropathy could be treated with Nav 1.7 antagonists, calcium channel blockers, anti-NGF antibodies, and angiotensin II type 2 receptor antagonists.

 

As part of its neuropathic pain treatment program, Novartis AG introduced Tegerton (carbamazepine), a new epilepsy drug designed to reduce nerve impulses that cause pain in diabetics.

 

Nucynta ER, a pain reliever derived from opioids, used to treat diabetes-induced nerve damage, was also launched by Janssen Pharmaceuticals.

 

Among the recommended treatment options for diabetic neuropathy, there are antidepressants like amitriptyline and duloxetine as well as topical agents like gabapentin and pregabalin analogues and opioids for pain relief in neuropathy.

 

In order to alleviate pain and improve quality of life associated with diabetic neuropathy, more research is needed on the most effective drugs or combinations.

 

Clinical Trials

In current therapies, sensory deficits and aetiology are not addressed, so there is an unmet demand for treatment options that target the natural course of the condition.

 

The outcomes of recent randomized controlled trials show that some of these pathological treatments improve neuropathic endpoints clinically. Patients with neuropathic pain remain undertreated with effective analgesic monotherapy as limited number of patients able to achieve clinically meaningful results.

 

New pharmaceutical approaches have been expanded due to increased knowledge of neurobiology and phenotypic profiling of neuropathic pain.

 

A number of promising molecular structures are in clinical development, which will soon improve our therapeutic arsenal of diabetic neuropathy treatments.

 

In diabetic neuropathy, the disease progresses over time. Medication and lifestyle changes can alleviate this condition. Medications that control diabetes are the most effective in slowing the onset of complications caused by diabetes.

 

The FDA has approved these drugs for treating diabetic neuropathy:

  • anticonvulsant Lyrica (pregabalin)
  • antidepressant Cymbalta (duloxetine)
  • opioid Nucinta (tapentadol)

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global diabetic neuropathy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • NeuroMetrix, Inc
  • Allergan PLC
  • Pfizer, Inc
  • Eli Lilly and Company
  • Novartis AG
  • Janssen Global Services, LLC
  • Teva Pharmaceutical Industries Ltd.
  • LUMITOS AG
  • GSK plc
  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals Ltd

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment Methods
  • Distribution Channels
  • End User
  • Region
Breakup by Type
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
Breakup by Treatment Methods
  • Antidepressants
  • Anti-seizure Medications
  • Anticonvulsants
  • Electric Nerve Stimulation
  • Topical Medications
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others
Breakup by End User
  • Hospitals
  • Research Institutes
  • Specialty Clinics
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • NeuroMetrix, Inc
  • Allergan PLC
  • Pfizer, Inc
  • Eli Lilly and Company
  • Novartis AG
  • Janssen Global Services, LLC
  • Teva Pharmaceutical Industries Ltd.
  • LUMITOS AG
  • GSK plc
  • Astellas Pharma Inc
  • Glenmark Pharmaceuticals Ltd

 

Diabetic Neuropathy Market Report Snapshots

Diabetic Neuropathy Market Size

Diabetic Neuropathy Analysis

Diabetic Neuropathy Treatment Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Diabetes Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Diabetes Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Diabetes Epidemiology (2016-2031)
    5.3    Europe Diabetes Epidemiology (2016-2031)
    5.4    Asia Pacific Diabetes Epidemiology (2016-2031)
    5.5    Latin America Diabetes Epidemiology (2016-2031)
    5.6    Middle East and Africa Diabetes Epidemiology (2016-2031)
6    Global Diabetic Neuropathy Market Overview 
    6.1    Global Diabetic Neuropathy Market Historical Value (2017-2023)
    6.2    Global Diabetic Neuropathy Market Forecast Value (2024-2032)
7    Global Diabetic Neuropathy Market Landscape
    7.1    Diabetic Neuropathy: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Diabetic Neuropathy: Product Landscape
        7.2.1    Analysis by Type 
        7.2.2    Analysis by Treatment Methods
        7.2.3    Analysis by Distribution Channels
        7.2.4    Analysis by End User
8    Diabetic Neuropathy Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Diabetic Neuropathy Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Diabetic Neuropathy Market Segmentation
    11.1    Global Diabetic Neuropathy Market by Type 
        11.1.1    Market Overview
        11.1.2    Peripheral Neuropathy
        11.1.3    Autonomic Neuropathy
        11.1.4    Proximal Neuropathy
        11.1.5    Focal Neuropathy
    11.2    Global Diabetic Neuropathy Market by Treatment Methods 
        11.2.1    Market Overview
        11.2.2    Antidepressants
        11.2.3    Anti-seizure Medications
        11.2.4    Anticonvulsants
        11.2.5    Electric Nerve Stimulation
        11.2.6    Topical Medications
        11.2.7    Others
    11.3    Global Diabetic Neuropathy Market by Distribution Channels
        11.3.1    Market Overview
        11.3.2    Hospital Pharmacy
        11.3.3    Retail Pharmacy
        11.3.4    Online Pharmacies
        11.3.5    Others
    11.4    Global Diabetic Neuropathy Market by End User
        11.4.1    Market Overview
        11.4.2    Hospitals
        11.4.3    Research Institutes
        11.4.4    Specialty Clinics
    11.5    Global Diabetic Neuropathy Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Diabetic Neuropathy Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Diabetic Neuropathy Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Diabetic Neuropathy Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Diabetic Neuropathy Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Diabetic Neuropathy Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    NeuroMetrix, Inc
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Allergan PLC
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Pfizer, Inc
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Eli Lilly and Company
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Novartis AG
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Janssen Global Services, LLC
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Teva Pharmaceutical Industries Ltd.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    LUMITOS AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    GSK plc
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Astellas Pharma Inc
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Glenmark Pharmaceuticals Ltd
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
24    Diabetic Neuropathy - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the market attained a value of USD 4.90 billion in 2023, driven by the increasing prevalence of diabetic patients across the globe.

The market size is anticipated to grow at a CAGR of 6.99% during the forecast period of 2024-2032 to achieve a value of USD 8.50 billion by 2032.

The rising cases of diabetes and launch of new products are the major factors driving the growth of the market.

North America has been leading the global market due to early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.

The high cost of the product and the availability of alternatives for diabetic neuropathy are hindering the market growth.

Diabetes causes nerve damage, which is known as diabetic neuropathy. Diabetes-related high blood glucose levels, also known as blood sugar, and high levels of fats in the blood, such as triglycerides, can damage nerves over time.

The signs and symptoms of peripheral neuropathy include numbness, prickling, or tingling in your feet or hands that can spread up into your legs and arms. Sharp, jabbing, throbbing, or burning discomfort Touch sensitivity to the extreme.

The types of the condition include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.

The treatment methods include antidepressants, anti-seizure medications, anticonvulsants, electric nerve stimulation, and topical medications, among others.

The distribution channels in the market include hospital pharmacy, retail pharmacy, and online pharmacies, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER